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dian OS 27.4 months. Patients treated at centers in Germany 
(n  = 97), Ireland (n  = 32), and The Netherlands (n  = 43) 
showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 
20.5, and 25.1 months, respectively. Patients >65 years had 
a significantly shorter PFS (9.5 vs. 9.8 months) but not OS 
(27.4 vs. 27.5 months) than younger patients. High tumor 
grade (G3/4) was associated with a shorter PFS, T4 classifica-
tion with both shorter PFS and OS. Fluoropyrimidine (FP) 
chemotherapy backbones (doublets and single) had compa-
rable outcomes, while patients not receiving FP backbones 
had a shorter PFS. In multivariable analysis, age and non-FP 
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 Abstract 
 Background/Aims: This study is aimed at analyzing the sur-
vival rates and prognostic factors of stage IV colorectal can-
cer patients from 3 European cohorts undergoing combina-
tion chemotherapy with bevacizumab.  Methods: Progres-
sion free-survival (PFS) and overall survival (OS) were 
analyzed in 172 patients using the Kaplan–Meier method 
and uni- and multivariable Cox proportional hazards regres-
sion models.  Results: The median PFS was 9.7 and the me-
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backbone were associated with inferior PFS, T4 classification 
and therapy line >2nd were significantly associated with 
poor PFS and OS.  Conclusion: The observed survival rates 
confirm previous studies and demonstrate reproducible 
benefits of combination bevacizumab regimens. Classifica-
tion T4, non-FP chemotherapy backbone, and age >65 were 
associated with inferior outcome.  © 2016 S. Karger AG, Basel 
 Introduction 
 Colorectal cancer (CRC) is globally a major cause of 
cancer morbidity and mortality, being the third most 
commonly diagnosed cancer in males and the second 
most common in females with more than 1.4 million new 
cancer cases diagnosed in 2012  [1] . Approximately, one 
third of patients initially present with metastases and al-
most 50% of patients diagnosed at early stage will eventu-
ally develop metastatic or irresectable locally advanced 
disease  [2] .
 The treatment of metastatic or irresectable CRC has 
since the late 1950s been based on fluoropyrimidine (FP) 
5-fluorouracil (5-FU), a nucleoside analog combined 
with calcium-folinate (leucovorin), leading to median 
survival rates of around 12 months  [3–5] . Outcome ben-
efits have been improved by adding oxaliplatin (e.g. 
FOLFOX)  [6] or irinotecan (e.g. FOLFIRI)  [7] , and 
monoclonal antibodies (cetuximab, panitumumab, beva-
cizumab), fusion proteins (aflibercept), and tyrosine ki-
nase inhibitors (regorafenib), leading to median overall 
survival (OS) rates of around 2 years  [8, 9] . Bevacizumab 
is a humanized monoclonal antibody against vascular en-
dothelial growth factor, one of the major growth factors 
involved in vessel formation, which is crucial for the 
growth and invasion of malignant cells  [10] . Randomized 
clinical trials have revealed a significant benefit in pro-
gression-free-survival (PFS) and OS, when bevacizumab 
is added to 5-FU based chemotherapy regimens  [11–19] .
 However, only a subset of patients respond to targeted 
agents such as bevacizumab, and the overall clinical 
 benefit is limited. Also, toxic side effects and high treat-
ment costs should be considered  [20] . Therefore, new 
methods to stratify patients before treatment with beva-
cizumab, based on predictive- and prognostic factors are 
urgently needed. Angiopredict (www.angiopredict.com) 
is a Framework Programme 7 (FP7) European Commis-
sion funded, multidisciplinary and multi-institutional re-
search project that seeks to identify predictive genomic 
biomarker signatures for metastatic CRC patients receiv-
ing combination bevacizumab therapy. Multi-omic mo-
lecular analyses are currently being performed on retro-
spectively retrieved samples from patients undergoing 
chemotherapy with or without bevacizumab therapy, col-
lected at centers in Ireland, the Netherlands, and  Germany. 
Validation of findings will be performed on tissues pro-
spectively collected in the ongoing AC-Angiopredict 
Phase II Exploratory trial (NCT01822444).
 Herein, we sought to evaluate the clinical and patho-
logical characteristics, the survival rates, and clinical 
prognostic factors in a pooled retrospective cohort of pa-
tients from the Angiopredict study that have been treated 
with combination bevacizumab therapy.
 Patients and Methods 
 Patients 
 Patients with advanced (locally irresectable or metastatic) CRC 
commencing combination chemotherapy including Bevacizumab 
between July 2004 and April 2012 were included in this analysis. 
Clinicopathological data were collected within 3 different cohorts: 
(1) University Hospital Mannheim, Heidelberg University, 
Mannheim, Germany (UHEI); (2) VU University Medical Center 
Amsterdam, the Netherlands and several other Dutch hospitals 
(VUMC); and (3) Royal College of Surgeons in Ireland, Beaumont 
Hospital, Dublin, Ireland (RCSI). Criteria for inclusion were: (1) 
histologically proven diagnosis of colon or rectum adenocarcino-
ma, either metastasized or locally advanced and irresectable, (2) 
combination chemotherapy with a regimen including bevacizum-
ab at any line of chemotherapy.
 T- and N-classifications, grading, and localization of the tumor 
samples were collected by reviewing patients’ records. T- and N-
classifications, and grading were routinely evaluated by different 
pathologists from the participating centers using AJCC/UICC and 
WHO guidelines, respectively  [21, 22] .
 Colon cancers located from caecum to hepatic flexure were de-
fined as right-sided cancers, and tumors located from transverse 
colon to sigmoid as left-sided. KRAS mutations in codons 12/13 
were assessed.
 Chemotherapy 
 Chemotherapy, administered together with Bevacizumab, in-
cluded the following regimens: (A) Fluoropyrimidine (FP)-based 
chemotherapy (5-fluorouracil (5-FU), 5-FU and leucovorin, 
capecitabine), (B) oxaliplatin doublets (FOLFOX, CapOX/XelOX, 
oxaliplatin and raltitrexed), (C) irinotecan doublets (FOLFIRI, Ca-
pIRI/XelIRI, irinotecan and raltitrexed) and (D) others (irinote-
can, oxaliplatin, mitomycin or no backbone). All patients from the 
VUMC cohort were treated with either FOLFOX or CapOX and 
bevacizumab.
 Follow-Up 
 The observation period for each patient commenced with the 
initiation of bevacizumab treatment. Clinical data for the 3 cohorts 
were routinely collected and documented by the treating physi-
cian. The follow-up period for the UHEI, VUMC and RSCI co-
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horts started on July 28, 2004, September 7, 2004, and August 18, 
2004, respectively. They ended on December 15, 2014, July 03, 
2013, and June 02, 2015, respectively. Follow-up included CT 
scans or abdominal ultrasound and chest X-ray every 3 months.
 Institutional Review Board approval was obtained from the re-
sponsible Ethics Committees for all participating study centers.
 Statistical Analysis 
 The data from the 3 cohorts were assessed via pooled analysis 
using individual patient data. Fisher’s exact test was used to com-
pare the distribution of clinicopathological factors between cen-
ters. PFS was defined as the time from start of bevacizumab ther-
apy to progressive disease or death from any cause, whichever oc-
curred first. Patients stopping bevacizumab therapy due to reasons 
other than progression or death were censored as of the date of 
treatment cessation. OS was defined as the time from start of bev-
acizumab to death from any cause. All patient data were adminis-
tratively censored after 60 months.
 Time to progression and death were retrospectively deter-
mined by chart review. PFS and OSs were investigated using the 
Kaplan–Meier method and compared by log-rank test or using 
Cox proportional hazards regression model. Log-rank tests and 
Cox regression were calculated with stratification by cohort to ad-
just for center effect.
 For multivariable Cox proportional hazards regression models, 
multiple imputation (B = 100) of missing values was performed 
using the predictive mean matching algorithm as implemented in 
R package Hmisc  [23] .
 All statistical calculations were performed using R (version 3.1, 
R Foundation for Statistical Computing, Vienna, Austria. http://
www.R-project.org/). All reported p values were 2-sided with sig-
nificance at p < 0.05.
 Results 
 Patient Characteristics 
 A total of 172 patients were included in this analysis. 
Of which, 97 patients were treated at UHEI, 32 at the 
RCSI, and 43 were part of the VUMC cohort.
 Fifty-four (31%) patients were females and 118 (69%) 
males, 115 (67%) had a primary colon and 57 (33%) a pri-
mary rectum cancer. The median age at the start of treat-
ment with bevacizumab was 65 years (mean 63.7, range 
27–84). Eighty patients (47%) were older than 65 years, 90 
patients (53%) were 65 years or younger. One hundred 
twenty nine patients (75%) were treated with a chemother-
apy regimen that included bevacizumab in first line, 33 
(19%) in second line, 10 (6%) in third or later lines. Fifty-
eight patients (34%) received an irinotecan doublet che-
motherapy backbone, 83 (48%) an oxaliplatin doublet. 
Twenty-four patients (14%) received bevacizumab togeth-
er with a FP monotherapy, 7 patients (4%) were treated 
with bevacizumab and irinotecan or with bevacizumab as 
monotherapy. Other patient characteristics are shown in 
 table 1 . Tumor grade was available for 146 patients, T clas-
sification for 160, N classification for 156 patients. Data 
regarding surgery of the primary tumor or of metastases 
could not be determined for all patients and could there-
fore not be analyzed for the pooled retrospective cohort. 
The 3 cohorts included differed significantly with respect 
to gender, age, T-classification, grading, location of the pri-
mary tumor, treatment line, and chemotherapy backbone.
 The median follow-up time was 48.1 months (95% CI 
40.5–56.2). The median follow-up times of the UHEI, 
RCSI, and VUMC cohorts were 30.9, 60.0, and 60.0 
months, respectively. At the end of follow-up, 121 pa-
tients (70%) experienced disease progression, 104 (60%) 
were deceased, while 68 patients (40%) were censored 
with respect to OS.
 Survival Analysis 
 Patients with CRC that underwent combination ther-
apy with bevacizumab had a median PFS of 9.67 months 
(95% CI 9.18–10.56) and a median OS of 27.4 months 
(95% CI 22.9–32.7;  fig. 1 a, b). Patients from UHEI, RCSI, 
and VUMC cohorts had a median PFS of 9.9, 9.2, and 9.7 
months, respectively. The OS of patients from UHEI, 
RCSI, and VUMC were 34.0, 20.5, and 25.1 months, re-
spectively.
 Patients who were older than 65 years at the start of 
treatment with bevacizumab had a significantly shorter 
PFS (9.5 vs. 9.8 months, p = 0.01), but no significant dif-
ference in the OS was observed (27.4 vs. 27.5 months, p = 
0.43) in patients following treatment with bevacizumab 
( fig. 2 a, b). Regarding gender, no statistically significant 
difference in the median PFS (females: 10 months vs. 
males: 9.5 months, p = 0.92) or median OS (females: 25.2 
months, vs. males: 27.5 months, p = 0.34) was observed.
 Higher tumor grades (G3–4 vs. G1–2) correlated with 
a shorter PFS (7 vs. 9.9 months, p = 0.033), but had no 
impact on OS (p = 0.77). Tumor localization (right-sided 
colon cancer, left-sided colon cancer, rectal cancer) had 
no significant influence on PFS of patients on bevacizum-
ab treatment (right-sided 9.2 months, left-sided 9.3 
months, rectum 10.4 months, p = 0.69). There was a trend 
towards worse OS of patients with right-sided colon can-
cer compared to patients with left sided cancers and rectal 
cancers (19.1, 31.9, and 25 months, respectively, p = 0.24). 
The presence of lymph node metastases had no signifi-
cant impact on the outcome regarding both PFS (N0: 10 
months, N1–2: 9.7 months, p = 0.58) and OS (N0: 28.3 
months, N1–2: 27.4 months, p = 0.64) in this setting of 
predominantly metastasized cancers. Of note, N-classifi-
cation had an age-dependent impact on PFS (interaction 
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p = 0.003): While N1–2 was of no prognostic impact in 
patients older than 65 years, younger patients ( ≤ 65) with 
positive lymph node status had shorter PFS (8.8 months) 
than with negative lymph nodes (14 months, p = 0.002). 
Tumor classification T4 (tumor penetration beyond vis-
ceral peritoneum or direct invasion into other organs or 
structures) at the time of diagnosis was significantly as-
sociated with both PFS (T1–T3: 10.3 months vs. T4: 6.8 
months, p = 0.004) and OS (T1–T3: 32 months vs. T4: 
20.5 months, p < 0.001). KRAS status could be obtained 
for 89 patients (52%). No significant impact on PFS or OS 
was observed in our cohort (PFS: p = 0.72, OS: p = 0.89).
 Regarding the chemotherapy backbone administered 
together with bevacizumab, significant differences in PFS 
were observed (p < 0.001). These differences were, how-
ever, mainly attributable to 7 patients receiving bevaci-
zumab with non-standard backbones that did not include 
a FP (irinotecan and bevacizumab; irinotecan, cetuximab 
and bevacizumab or bevacizumab monotherapy, PFS = 
3.2 months), while all other backbones had similar PFS 
(irinotecan-doublets: 10.3 months, oxaliplatin-doublets: 
9.7 months, FP-single: 10.4 months;  fig 2 c). No signifi-
cant differences in OS were found regarding chemother-
apy backbones (p = 0.58;  fig 2 d). Patients receiving beva-
Table 1.  Characteristics of patients treated with bevacizumab
UHEI RCSI VUMC  All p value
n % n % n %  n %
Gender <0.001
Female 37 38 4 13 13 30 54 31
Male 60 62 28 88 30 70 118 69
Age, years 0.001
>65 57 59 12 40 11 26 80 47
≤65 40 41 18 60 32 74 90 53
T-classification 0.005
1 4 4 0 0 0 0 4 3
2 13 14 2 7 4 10 19 12
3 53 59 12 41 32 78 97 61
4 20 22 15 52 5 12 40 25
N-classification 0.49
Negative 30 35 7 23 12 30 49 31
Positive 56 65 23 77 28 70 107 69
Tumor grade <0.001
Low (1–2) 46 60 27 96 35 85 108 74
High (3–4) 31 40 1 4 6 14 38 26
Localization 0.038
Right-sided 16 17 12 39 8 20 36 21
Left-sided 43 44 17 55 20 48 80 47
Rectum 38 39 2 6 14 33 54 32
KRAS 0.68
wt 34 65 11 65 11 55 56 63
mut 18 35 6 35 9 45 33 37
BVZ therapy line <0.001
>1 60 62 26 81 43 100 129 75
>2 29 30 4 13 33 19
≥3 8 8 2 6 10 6
CTX backbone <0.001
FP single 22 23 2 6 24 14
IRI doublet 51 53 7 22 58 34
OX doublet 21 22 19 59 43 100 83 48
Other 3 3 4 13 7 4
Total 97 100 32 100 43 100 172 100
wt = wild-type; mut = mutated; IRI = irinotecan; OX = oxaliplatin; CTX = chemotherapy; BVZ = bevacizumab. 
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cizumab in first line (n = 129), second line (n = 33) or in 
third line or later lines (n = 10) had a median PFS of 9.8, 
9.9, and 5.5 months (p = 0.06). The median OS of patients 
treated in first line, second line, or later lines were 27.4, 
32.7, and 21.3 months (p = 0.09), respectively.
 Univariable Cox analyses of PFS and OS of all patients 
following treatment with bevacizumab are shown in  ta-
ble 2 . In accordance with Kaplan–Meier analysis, age >65 
years, higher tumor grade, T4 classification, treatment 
line >2nd, and non-FP chemotherapy backbone were as-
sociated with a shorter PFS, while treatment line >2nd 
and classification T4 predicted poor OS.
 In a multivariable Cox proportional hazards regres-
sion model, a non-FP chemotherapy backbone and T4 
classification were independently associated with adverse 
PFS. T4 classification and treatment line >2nd were inde-
pendently associated with adverse OS ( table 3 ).
 Discussion 
 Bevacizumab has emerged as an important compo-
nent of palliative therapy in CRC. According to the data 
presented here, patients with CRC receiving bevacizum-
ab in combination with chemotherapy had a median PFS 
of 9.8 months and a median OS of 23.7 months. PFS and 
OS in our cohorts are comparable with survival data from 
prospective clinical trials, in which a PFS of 7.3–10.3 
months and an OS of 10.8–25.3 months have been ob-
served  [11, 13–15, 17, 19, 24–28] .
 The choice of chemotherapy (-backbone) regimen is 
important in the palliative treatment of CRC patients. To 
date, it has been mainly based on potential side effects, co-
morbidities, and preferences of patient and physician  [29] . 
According to our findings, the chemotherapy backbone ad-
ministered together with bevacizumab had no significant 
influence on either PFS or OS of patients, if a standard FP-
based regimen was used. This is in accordance with previ-
ous studies, in which a median PFS of around 9–12 months 
and OS >20 months have been reported, regardless of che-
motherapy (-doublet) used as backbone  [29, 30] . Patients 
receiving backbones without a FP or without concomitant 
chemotherapy had significantly worse outcomes. It is pos-
sible that patients not receiving a FP did not receive a more 
debilitating chemotherapy due to co-morbidities, low per-
formance status or frailty. Unfortunately, these factors 
could not be analyzed in this retrospective study. Neverthe-
less, it may be useful to discuss best supportive care with a 
patient in such a scenario, since the benefit of bevacizumab 
without chemotherapy or with non-standard backbones 
seems to be limited. Interestingly, patients treated with ox-
aliplatin or irinotecan doublets did not have longer PFS or 
OS than patients receiving only 5-FU or capecitabine to-
gether with bevacizumab. This may be explained by a larg-
er fraction of elderly patients in our cohort that may ben-
efit less from doublets and perform better with single 5-FU 
or capecitabine together with bevacizumab. However, 
since only about 15% of our patients were treated with 5-FU 
or capecitabine and bevacizumab alone, the statistical pow-
er of our analysis is weakened due to the small sample size.
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 Fig. 1. PFS and OS of 172 CRC patients treated with bevacizumab. Kaplan–Meier analysis of ( a ) PFS and ( b ) OS 
of 172 patients treated with bevacizumab. 
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 Regarding other clinicopathological factors, mor-
phological grading of the primary tumor has an influ-
ence on PFS, but not on OS. Interestingly, even in the 
setting of patients with metastasized disease and mainly 
after resection of the primary tumor, T4 classification 
was significantly associated with worse PFS and OS and 
remained significantly associated with both PFS and OS 
in multivariable Cox analysis. This finding suggests that 
local tumor spread or recurrence may be a relevant, to 
date potentially underestimated prognostic determi-
nant in metastasized CRC. Literature on the prognostic 
impact of pathologic variables of the primary tumor in 
 Fig. 2. Clinical prognostic factors influencing the survival of CRC 
patients treated with bevacizumab. Elderly patients >65 years had 
significantly shorter PFS ( a ) but not OS ( b ) than younger patients 
under chemotherapy with bevacizumab. PFS ( c ) and OS ( d ) are 
affected by the backbone chemotherapy regimen administered to-
gether with bevacizumab in Kaplan–Meier analysis due to shorter 
survival rates of patients receiving non-FP-backbones. 
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patients undergoing chemotherapy for metastasized 
CRC is rare. A retrospective study of 788 patients with 
metastasized CRC presented classification T3 or T4 and 
high tumor grade, and also presence of nodal disease 
(N1/N2), diffuse metastasis, high CEA levels and low 
Albumin levels to be significantly associated with ad-
verse outcome after resection of the primary tumor  [31] . 
In our series, lymph node status, tumor localization 
(right colon, left colon, rectum), and gender of the pa-
tients did not show an impact on the outcome. KRAS 
status could be obtained only from around 50% of the 
patients, most likely because KRAS status was not rou-
tinely tested in all patients when the majority of our co-
hort started treatment with bevacizumab. A prognostic 
impact on the outcome was not noted for KRAS status 
in our cohort.
Table 2.  Univariable Cox analysis of prognostic factors under chemotherapy with bevacizumab
Variable Level n PFS  OS
HR 95% CI p value HR 95% CI p value
Gender male vs. female 172 1.02 0.68–1.53 0.91 0.80 0.51–1.26 0.35
Age >65 vs. ≤65 170 1.66 1.12–2.46 0.011 1.19 0.77–1.82 0.43
T 4 vs. 1–3 160 1.97 1.24–3.13 0.004 2.21 1.37–3.57 0.001
N 1–2 vs. 0 156 1.12 0.74–1.7 0.59 1.11 0.71–1.73 0.64
Grading high vs. low 146 1.74 1.04–2.9 0.034 1.09 0.61–1.97 0.77
Localization right vs. left 170 1.13 0.70–1.82 0.63 1.47 0.91–2.40 0.12
rectum vs. left 0.88 0.56–1.37 0.56 0.97 0.60–1.58 0.90
KRAS mut vs. wt 89 0.91 0.54–1.53 0.71 1.04 0.59–1.82 0.89
Line 2 vs. 1 172 0.92 0.54–1.55 0.74 1.28 0.71–2.31 0.40
>2 vs. 1 2.71 1.11–6.59 0.028 2.81 1.07–7.41 0.037
Backbone IRI doubl vs. FP 172 0.90 0.48–1.68 0.74 1.25 0.59–2.65 0.57
OX doubl vs. FP 1.12 0.56–2.24 0.75 1.01 0.43–2.40 0.97
other vs. FP 8.62 2.83–26.19 <0.001 1.91 0.56–6.50 0.30
 n = Number; HR = hazard ratio; p = wald p value; m = male; f = female; mut = mutated; wt = wild-type; dou-
bl = doublet; IRI = irinotecan; OX = oxaliplatin.
Table 3.  Multivariable Cox proportional hazards regression analysis of prognostic factors in 172 patients receiv-
ing chemotherapy with bevacizumab
Variable Level PFS  OS
HR 95% CI p value HR 95% CI p value
Gender male 0.98 0.60–1.58 0.92 0.69 0.42–1.15 0.15
Age >65 1.76 1.14–2.70 0.010 1.19 0.74–1.90 0.47
T 4 2.03 1.22–3.40 0.0067 2.47 1.45–4.19 <0.001
N positive 0.96 0.60–1.53 0.85 1.11 0.65–1.89 0.70
G high 1.30 0.73–2.23 0.37 0.82 0.42–1.60 0.56
Localization right 1.25 0.73–2.13 0.42 1.66 0.97–2.82 0.06
rectum 1.05 0.62–1.78 0.85 1.01 0.59–1.74 0.97
KRAS mut 0.96 0.55–1.67 0.88 0.98 0.54–1.78 0.94
Line 2nd 1.15 0.63–2.10 0.65 1.33 0.72–2.43 0.36
>2nd 3.34 1.28–8.71 0.014 4.02 1.39–11.62 0.010
Backbone IRI doubl 1.11 0.56–2.16 0.77 1.25 0.56–2.79 0.59
OX doubl 1.28 0.59–2.80 0.53 0.89 0.36–2.21 0.81
other 11.28 3.49–36.42 <0.001 2.51 0.72–8.74 0.15
 n = Number; HR = hazard ratio; p = wald p value; mut = mutated; IRI = irinotecan; OX = oxaliplatin.
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 According to our findings, patients older than 65 years 
had significantly shorter PFS than younger patients fol-
lowing treatment with bevacizumab. The difference, 
however, accounted only for a few weeks and no differ-
ence in OS was observed. A decrease in OS of elderly pa-
tients receiving bevacizumab compared to younger pa-
tients has been reported by observational studies and sub-
group analyses of clinical trials  [32–35] . Slight reductions 
in both PFS and OS were observed in patients  ≥ 70 years 
compared to younger patients treated with first-line bev-
acizumab-combination regimens in a large German ob-
servational study  [36] . However, a subgroup analysis 
from the AGTIG MAX trial found similar benefits of add-
ing bevacizumab to capecitabine in elderly patients >75 
years to those <75 years  [37] . Furthermore, according to 
the prospective AVEX trial that specifically evaluated el-
derly patients, capecitabine and bevacizumab was an ef-
fective regimen for this group of patients  [25] . According 
to a systematic review, benefits of bevacizumab in elderly 
patients do not appear to be significantly different from 
those reported in younger patients  [34] . Therefore, it is 
questionable if the differences observed in the PFS be-
tween elderly and younger patients found in our analysis 
and previous studies are clinically relevant.
 In addition to the 3 single center cohorts analyzed and 
presented in this study, a subgroup of patients enrolled in 
the CAIRO2 trial (randomized phase III study of 
capecitabine, oxaliplatin, bevacizumab with or without 
cetuximab in first-line advanced CRC) that underwent 
first-line combination chemotherapy with CapOX and 
bevacizumab (Arm A) at centers in the Netherlands has 
been included in the genomic analysis studies conducted 
within Angiopredict. The clinical characteristics of these 
patients have previously been described  [18] .
 Data presented here comprised of 3 different retro-
spective cohorts collected by chart review. Nevertheless, 
the PFS for all 3 cohorts was similar, highlighting the re-
producible benefits of a combination bevacizumab regi-
men even within heterogeneous cohorts. Data on OS dif-
fered, especially with respect to patients from the UHEI 
cohort, for whom OS was significantly longer. It is not 
possible to definitely ascertain the underlying reason for 
this difference in this retrospective study. A possible rea-
son may be a higher proportion of patients undergoing 
(curative) resection of metastases or interventional thera-
pies following bevacizumab administration within the 
UHEI cohort. When patients with resected metastasis 
were excluded from the UHEI cohort, the difference 
compared with other cohorts was reduced and no longer 
significant (data not shown). Data on resection of metas-
tases was not available for the other cohorts. Nevertheless, 
survival rates of up to 34 months have also been reported 
in other CRC studies and clinical trials  [28, 30] . To ac-
count for the possible cohort effect, all survival analyses 
(log-rank, Cox-regression) were performed with stratifi-
cation by center.
 Our analyses have further limitations. First, with re-
spect to the retrospective nature of our study, we observed 
comparatively long survival rates in 2nd and 3rd line pa-
tients included in our analysis, which may be explained 
by selection bias. Also, ECOG status of our patients and 
adverse effects as a consequence of combination bevaci-
zumab therapy were not analyzed in this study.
 In conclusion, our data demonstrate that the survival 
of CRC patients receiving combination chemotherapy 
with bevacizumab was comparable to prospective clinical 
studies, providing evidence for demographically repre-
sentative cohorts. A non-FP chemotherapy backbone was 
significantly associated with adverse outcome, while all 
standard combinations (doublets and single FP) resulted 
in comparable survival rates. T4 classification was associ-
ated with shorter PFS and OS, while age >65 years and 
high tumor grade were found to be associated with short-
er PFS but not OS.
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